Detalhe da pesquisa
1.
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
Blood
; 143(5): 404-416, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37890149
2.
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Blood
; 141(14): 1675-1684, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36542826
3.
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
Blood
; 139(12): 1794-1806, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34699592
4.
Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.
Future Oncol
; 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38547003
5.
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Lancet
; 399(10343): 2294-2308, 2022 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717989
6.
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
Lancet Oncol
; 23(8): 1066-1077, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35839786
7.
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Lancet
; 396(10254): 839-852, 2020 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32888407
8.
Recurrent or progressive pediatric brain tumors: population pharmacokinetics and exposure-response analysis of pomalidomide.
Pediatr Res
; 90(4): 832-839, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33469186
9.
Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.
Mol Pharm
; 15(7): 2621-2632, 2018 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29792708
10.
Multiplex and Label-Free Relative Quantification Approach for Studying Protein Abundance of Drug Metabolizing Enzymes in Human Liver Microsomes Using SWATH-MS.
J Proteome Res
; 16(11): 4134-4143, 2017 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28944677
11.
Pharmacokinetics of total and unbound prednisone and prednisolone in stable kidney transplant recipients with diabetes mellitus.
Ther Drug Monit
; 36(4): 448-55, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24452065
12.
Mapping Colorectal Distribution of Cell-free and Cell-associated HIV Surrogates Following Simulated Anal Intercourse to Aid Rectal Microbicide Development.
J Acquir Immune Defic Syndr
; 2024 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38346420
13.
An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR-T and TCR-T Cellular Therapies Development.
Clin Pharmacol Ther
; 115(2): 188-200, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37983584
14.
Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus.
Xenobiotica
; 43(3): 229-35, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22934787
15.
Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism.
Xenobiotica
; 43(7): 641-9, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23278282
16.
Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies: An Industry Perspective.
Clin Pharmacol Ther
; 114(3): 530-557, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37393588
17.
Relative bioavailability of fedratinib through various alternative oral administration methods in healthy adults.
Cancer Chemother Pharmacol
; 2023 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37955741
18.
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.
J Clin Oncol
; : JCO2302214, 2023 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38072625
19.
In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma.
Clin Pharmacol Ther
; 112(1): 81-89, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35156195
20.
Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults.
Cancer Chemother Pharmacol
; 90(4): 325-334, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36001108